The purpose of the study is to evaluate the pharmacokinetics, safety and tolerability of UCB0942 in Japanese and Caucasian subjects.

Inclusion Criteria:

• Subject is male or female and between 20 and 55 years of age (inclusive)
• Subject is in good physical and mental health
• Female subjects will use an efficient form of contraception for the duration of the study (unless menopausal)
• Male subject agrees that, during the study period, when having sexual intercourse with a woman of childbearing potential, he will use an efficient barrier contraceptive AND that the respective partner will use an additional efficient contraceptive method
• For Japanese subjects: Subject is of Japanese descent as evidenced by appearance and verbal confirmation of familial heritage (a subject has all 4 Japanese grandparents born in Japan)
• For Caucasians: Subject is of Caucasian descent as evidenced by appearance and verbal confirmation of familial heritage (a subject has 4 Caucasian grandparents).

Exclusion Criteria:

At screening:

• Previous study participation with another investigational medicinal product (IMP) within 3 months
• History of alcohol/drug abuse
• History of psychiatric condition and suicide attempt
• Any medical condition unfit for study (including history of cancer)
• History of hypersensitivity for IMP components
• Taking concomitant medications
• Positive for human immunodeficiency virus (HIV)/ hepatitis B virus (HBV)/ hepatitis C virus (HCV)
• Abnormal liver function tests (LFTs), abnormal safety bloods/ vitals/ physical examination and electrocardiogram (ECG) findings
• Positive for pregnancy test
• Other protocol-defined exclusion criteria may apply